CONMED Corporation
NYSE:CNMDMedical - Devices
+$0.24 today
- Market cap
- $1.43B
- Beta
- 0.92
- P/E (TTM)
- 18.0
- EPS (TTM)
- $1.79
- Dividend yield
- 1.24%
Volume 0.36M
Average 0.45M
CNMD Interest Expense
Cost of servicing the company's debt during the period.
CONMED CorporationNYSE: CNMD
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense declines year over year
Q1 FY2026 interest expense of $7.06M fell 14.8% year over year, ahead of the -17.0% change in trailing-twelve-month interest expense. Sequentially, it fell 4.2% from the prior quarter. Over 3 fiscal years it compounded at +2.5% a year.
Context
- Interest expense amounted to 2.3% of revenue in FY2025, down 0.6 pp from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -14.8% holds above the trailing-twelve-month pace of -17.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 31.09M USD
- Year-over-year change
- -16.7%
- 4-year CAGR
- -3.3%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.09M | -16.7% |
| FY2024 | 2024-12-31 | 37.3M | -6.2% |
| FY2023 | 2023-12-31 | 39.78M | +37.6% |
| FY2022 | 2022-12-31 | 28.91M | -18.5% |
| FY2021 | 2021-12-31 | 35.49M | — |
Interest Expense vs competitors
How CNMD compares with its peers on the latest reported figures
- CNMD's LTM Mar 2026 interest expense of $29.86M is the 3rd highest of the 11 companies compared; the peer median is $4.93M.
- Its year-over-year change of -17.0% is the 5th highest of 7, against a peer median of -4.7%.
- Interest expense amounts to 2.2% of revenue for CNMD, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $102.95M | -16.0% | -1.1% | 3.6% | |
| LTM Aug 2026 | $56.45M | -18.7% | +1.0% | 6.4% | |
| LTM Mar 2026 | $29.86M | -17.0% | +2.5% | 2.2% | |
| LTM Sep 2026 | $28.18M | +17.6% | +29.0% | 10.7% | |
| LTM Jun 2026 | $7.77M | -37.0% | +52.5% | 1.2% | |
| LTM Jan 2026 | $7.46M | +6.7% | — | 8.9% | |
| LTM Mar 2026 | $2.4M | — | — | 0.4% | |
| LTM Mar 2026 | $1.01M | +8.0% | +89.9% | 2.1% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CNMD) | $4.93M | -4.7% | +29.0% | 1.7% | |
Competitors are the stored peer set for CNMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.01B | 1.05B | 1.24B | 1.31B | 1.37B |
| Cost of Revenue | 442.6M | 474.23M | 568.5M | 573.98M | 649.12M |
| Gross Profit | 568.04M | 571.25M | 676.25M | 733.03M | 725.38M |
| Gross Margin | 56.2% | 54.6% | 54.3% | 56.1% | 52.8% |
| Research & Development | 43.57M | 47.15M | 52.6M | 54.43M | 55.88M |
| Selling, General & Admin | 414.75M | 454.04M | 503.04M | 478.28M | 528.36M |
| Operating Expenses | 458.32M | 501.19M | 555.64M | 532.71M | 584.24M |
| Depreciation & Amortization | 70.74M | 49.76M | 71.87M | 71.86M | 52.34M |
| EBITDA | 179.33M | 7.8M | 192.48M | 272.18M | 154.55M |
| EBITDA Margin | 17.7% | 0.7% | 15.5% | 20.8% | 11.2% |
| Operating Income | 109.72M | 70.05M | 120.6M | 200.33M | 141.13M |
| Operating Margin | 10.9% | 6.7% | 9.7% | 15.3% | 10.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 35.49M | 28.91M | 39.78M | 37.3M | 31.09M |
| Other Income / Expenses | (36.61M) | (140.92M) | (39.78M) | (37.3M) | (70.01M) |
| Income Before Tax | 73.11M | (70.86M) | 80.83M | 163.03M | 71.12M |
| Pre-Tax Margin | 7.2% | -6.8% | 6.5% | 12.5% | 5.2% |
| Income Tax Expense | 10.56M | 9.72M | 16.37M | 30.61M | 24.06M |
| Net Income | 62.54M | (80.58M) | 64.46M | 132.42M | 47.06M |
| Net Margin | 6.2% | -7.7% | 5.2% | 10.1% | 3.4% |
| EPS (Basic) | 2.14 | (2.68) | 2.10 | 4.29 | 1.52 |
| EPS (Diluted) | 1.94 | (2.68) | 2.04 | 4.26 | 1.51 |
| Weighted Avg Shares | 29.16M | 30.04M | 30.67M | 30.85M | 31.04M |
| Weighted Avg Shares (Diluted) | 32.22M | 30.04M | 31.55M | 31.11M | 31.15M |
CONMED Corporation
NYSE:CNMD
Intrinsic Alpha fair value
Locked
Current Price
$48.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.